Reflections on telomeres, growth, aging, and essential hypertension

Hypertension

Volumn 29, Issue 5, 1997, Pages 1067-1072

  Aviv, Abraham ^a   Aviv, Hana ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

aging; atherosclerosis; chromosomes; diabetes mellitus; genetics; kidney; telomere

Indexed keywords

AGING; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; ESSENTIAL HYPERTENSION; GROWTH RATE; HUMAN; KIDNEY DEVELOPMENT; NONHUMAN; PREMATURE AGING; PRIORITY JOURNAL; TELOMERE;

EID: 0030940276     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.29.5.1067     Document Type: Article

References (69)

1. Strohman RC. Ancient genomes, wise bodies, unhealthy people: limits of a genetic paradigm in biology and medicine. Perspect Biol Med. 1993;37:112-145.
2. Harley CB. Telomere loss: mitotic clock or genetic time bomb? Mutat Res. 1991;256:271-282.
3. Martin GM. Genetic modulation of telomeric terminal restriction-fragment length: relevance for clonal aging and late-life disease. Am J Hum Genet. 1994;55:866-869.
4. Broccoli D, Cooke H. Aging, healing and the metabolism of telomeres. Am J Hum Genet. 1993;52:657-660.
5. Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC. Telomere reduction in human colorectal carcinoma and with ageing. Nature. 1990;346:866-868.
6. Vaziri H, Schachter F, Uchida I, Wei L, Zhu X, Effros R, Cohen D, Harley CB. Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. Am J Hum Genet. 1993;52:661-667.
7. Slagboom PE, Droog S, Boomsma DI. Genetic determination of telomere size in humans: a twin study of three age groups. Am J Hum Genet. 1994;55:876-882.
8. Kipling D. Telomerase: immortality enzyme or oncogene? Nat Genet. 1995;9:104-106.
9. Collins K. Structure and function of telomerase. Curr Opin Cell Biol. 1996;8:374-380.
10. DeLang T. Telomere dynamics and genome instability in human cancer. In: Blackhorn EH, Greider CW, eds. Telomeres. Plainview, NY: Cold Spring Harbor Laboratory Press; 1995:265-293.
11. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011-2015.
12. Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB, Bacchetti S. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 1992;11:1921-1929.
13. Counter CM, Botelho FM, Wang P, Harley CB, Bacchetti S. Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein-Barr virus transformed human B lymphocytes. J Virol. 1994;68:3410-3414.
14. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J. 1995;14:4240-4248.
15. Broccoli D, Young JW, deLange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci U S A. 1995; 92:9082-9086.
16. Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet. 1996;18:173-179.
17. Blasco MA, Funk W, Villeponteau B, Greider CW. Functional characterization and developmental regulation of mouse telomerase RNA. Science. 1995;269:1267-1270.
18. Prowse KR, Greider CW. Developmental and tissue-specific regulation of mouse telomerase and telomere length. Proc Natl Acad Sci U S A. 1995;92:4818-4822.
19. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature. 1990;345:458-460.
20. Allsopp RC, Vaziri H, Patterson C, Goldstein S, Younglai EV, Futcher AB, Greider CW, Harley CB. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci U S A. 1992;89:10114-10118.
21. Schulz VP, Zakian VA, Ogburn CE, McKay J, Jarzebowicz AA, Edland SD, Martin GM. Accelerated loss of telomeric repeats may not explain accelerated replicative decline of Werner syndrome cells. Hum Genet. 1996;97:750-754.
22. Tanner JM, Healey MJR, Lockhart RD, Mckenzie JD, Whitehouse RH. Aberdeen Growth Study I: the prediction of adult body measurements from measurements taken each year from birth to 5 years. Arch Dis Child. 1956;31:372-381.
23. Law CM, Shiell AW. Is blood pressure related to birth weight? The strength of evidence from a systematic review of the literature. J Hypertens. 1996;14:935-941.
24. Schork NJ, Jokelainen P, Grant EJ, Schork MA, Weder AB. Relationship of growth and blood pressure in inbred rats. Am J Physiol. 1994;266:R702-R708.
25. Lever AF, Harrap SB. Essential hypertension: a disorder of growth with origin in childhood? J Hypertens. 1992;10:101-120.
26. Woynarowska B, Mukherjee D, Roche AF, Siervogel RM. Blood pressure changes during adolescence and subsequent adult blood pressure level. Hypertension. 1985;7:695-701.
27. Luke RG. Essential hypertension: a renal disease? A review and update of the evidence. Hypertension. 1993;21:380-390.
28. Churchill PC, Churchill MC, Bidani AK. Kidney cross transplants in Dahl salt-sensitive and salt-resistant rats. Am J Physiol. 1992;262: H1809-H1817.
29. Rettig R, Folberth C, Stauss H, Kopf D, Waldherr R, Unger T. Role of the kidney in primary hypertension: a renal transplantation study in rats. Am J Physiol. 1990;258:F601-F611.
30. Guidi E, Menghetti D, Milani S, Montagnino G, Palazzi P, Bianchi G. Hypertension may be transplanted with the kidney in humans: a long-term historical prospective follow-up of recipients grafted with kidneys coming from donors with and without hypertension in their families. J Am Soc Nephrol. 1996;7:1131-1138.
31. Mackenzie HS, Brenner BM. Fewer nephrons at birth: a missing link in the etiology of essential hypertension? Am J Kidney Dis. 1995;26:91-98.
32. Brenner BM, Chertow GM. Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury. Am J Kidney Dis. 1994;23:171-175.
33. Weder AB, Schork NJ. Adaptation, allometry, and hypertension. Hypertension. 1994;24:145-156.
34. Chevalier RL. Developmental renal physiology of the low birth weight pre-term newborn. J Urol. 1996;156:714-719.
35. Nyengaard JR, Bendtsen TF. Glomerular number and size in relation to age, kidney weight, and body surface in normal man. Anat Rec. 1992;232:194-201.
36. Hayslett JP. Functional adaptation to reduction in renal mass. Physiol Rev. 1979;59:137-164.
37. Glazebrook KN, McGrath FP, Steele BT. Prenatal compensatory renal growth: documentation with US. Radiology. 1993;189:733-735.
38. Mandell J, Peters CA, Estroff JA, Allred EN, Benacerraf BR. Human fetal compensatory renal growth. J Urol. 1993;150:790-792.
39. Fine L. The biology of renal hypertrophy. Kidney Int. 1986;29: 619-634.
40. Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension. 1996;27:481-490.
41. Langley-Evans S, Jackson A. Intrauterine programming of hypertension: nutrient-hormone interactions. Nutr Rev. 1996;54:163-169.
42. Barker DJP. Growth in utero and coronary heart disease. Nutr Rev. 1996;54:S1-S7.
43. Edwards CRW, Benediktsson R, Lindsay RS, Sekl JR. Dysfunction of placental glucocorticoid barrier: link between fetal environment and adult hypertension? Lancet. 1993;341:355-357.
44. Merlet-Benichou C, Gilbert T, Muffat-Joly M, Lelievere-Pegorier M, Leroy B. Intrauterine growth retardation leads to a permanent nephron deficit in the rat. Pediatr Nephrol. 1994;8:175-180.
45. Beaulac-Baillargeon L, Desrosiers C. Caffeine-cigarette interaction on fetal growth. Am J Obstet Gynecol. 1987;157:1236-1240.
46. Rawlings JS, Rawlings VB, Read JA. Prevalence of low birth weight and preterm delivery in relation to the interval between pregnancies among white and black women. N Engl J Med. 1995;332: 69-74.
47. Mune T, Rogerson FM, Nikkila H, Agarwal AK, White PC. Human hypertension caused by mutations in the kidney isozyme of 11β-hydroxysteroid dehydrogenase. Nat Genet. 1995;10:394-399.
48. Watson B, Bergman SM, Myracle A, Callen DF, Acton RT, Warnock DG. Genetic association of 11β-hydroxysteroid dehydrogenase type 2 (HSD11B2) flanking microsatellites with essential hypertension in blacks. Hypertension. 1996;28:478-482.
49. Reaven GM. Insulin resistance, hyperinsulinemia, and hypertriglyceridemia in the etiology and clinical course of hypertension. Am J Med. 1991;90(suppl 2A):7S-12S.
50. Williams RR, Hunt SC, Hasstedt SJ, Hopkins PN, Wu LL, Berry TD, Stults BM, Barlow GK, Schumacher MC, Lifton RP, Lalouel JM. Multigenic human hypertension: evidence for subtypes and hope for haplotypes. J Hypertens. 1990;8(suppl 7):S39-S46.
51. Chang E, Harley CB. Telomere length and replicative aging in human vascular tissues. Proc Natl Acad Sci USA. 1995;92:11190-11194.
52. Owens GK. Control of hypertrophic versus hyperplastic growth of vascular smooth muscle cells. Am J Physiol. 1989;257:H1755-H1765.
53. Hamet P, Richard L, Dam T-V, Teiger E, Orlov SN, Gaboury L, Gossard F, Tremblay J. Apoptosis in target organs of hypertension. Hypertension. 1995;26:642-648.
54. Heagerty AM, Aalkjaer C, Bund SJ, Korsgaard N, Mulvany MJ. Small artery structure in hypertension: dual processes of remodeling and growth. Hypertension. 1993;21:391-397.
55. Comi P, Chiaramonte R, Maier JAM. Senescence-dependent regulation of type 1 plasminogen activator inhibitor in human vascular endothelial cells. Exp Cell Res. 1995;219:304-308.
56. Goldstein S, Moerman EJ, Fujii S, Sobel BE. Overexpression of plasminogen activator inhibitor type-1 in senescent fibroblasts from normal subjects and those with Werner syndrome. J Cell Physiol. 1994;161:571-579.
57. Auwerx J, Bouillon R, Collen D, Geboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis. 1988;8:68-72.
58. Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud MF, Allan C. Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor. Diabete Metab. 1987;13:331-336.
59. Hamsten A, Wiman B, DeFaire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. M Engl J Med. 1985;313: 1557-1563.
60. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA. 1989;89:6998-7002.
61. Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EKO. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb. 1993;13:1090-1100.
62. Moerman EJ, Thweatt R, Moerman AM, Jones RA, Goldstein S. Insulin-like growth factor binding protein-3 is overexpressed in senescent and quiescent human fibroblasts. Exp Gerontol. 1993;28: 361-370.
63. Goldstein S, Moerman EJ, Baxter RC. Accumulation of insulin-like growth factor binding protein-3 in conditioned medium of human fibroblasts increases with chronologic age of donor and senescence in vitro. J Cell Physiol. 1993;156:294-302.
64. Goldstein S. Cellular senescence. In: DeGroot LJ, Cahill GF Jr, Odell WD, Martini L, Potts JT Jr, Nelson DH, Steinberger E, Winegard AI, eds. Endocrinology. 2nd ed. New York, NY: Grune & Stratton; 1989:2525-2549.
65. Rosskopf D, Hartung K, Hense J, Siffert W. Enhanced immunoglobulin formation of immortalized B cells from hypertensive patients. Hypertension. 1995;26:432-435.
66. + antiporter phenotype. abundance, and phosphorylation of immortalized lymphoblasts from humans with hypertension. Hypertension. 1995;25:971-977.
67. Gillum RF, Mussolino ME. White blood cell count and hypertension incidence: the NHANES I epidemiologic follow up study. J Clin Epidemiol. 1994;47:911-919.
68. Wright WE, Shay JW. Time, telomeres and tumours: is cellular senescence more than anticancer mechanism? Trends Cell Biol. 1995;5:293-296.
69. Hamet P. Cancer and hypertension: an unresolved issue. Hypertension. 1996;28:321-324.